<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080140</url>
  </required_header>
  <id_info>
    <org_study_id>1606YAS141008</org_study_id>
    <nct_id>NCT05080140</nct_id>
  </id_info>
  <brief_title>Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study</brief_title>
  <official_title>Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Misr University for Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Misr University for Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled pharmacokinetic based study will be carried out on patients with&#xD;
      both sexes and various ages, plasma triglycerides levels, clinical health disorders and using&#xD;
      different agents for treatment of their hyperlipidemia in order to access the optimal drug&#xD;
      therapy with best cost effectiveness in the elderly cases under investigation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">March 20, 2022</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Total cholesterol</measure>
    <time_frame>3 months</time_frame>
    <description>reduction of LDL</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Hyperlipidemia; Mixed</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega -3 fatty acids-</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin+ Ezetimibe</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastain + ezetimibe + omega</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10mg</intervention_name>
    <description>Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_label>Simvastain + ezetimibe + omega</arm_group_label>
    <arm_group_label>Simvastatin+ Ezetimibe</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        least 80 adult patients both sexes suffering from mixed dyslipidemia with high triglyceride&#xD;
        level admitted at Sauad Kaffafi Hospital, Misr University for science and technology.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of dyslipidemia with high triglyceride level (200 to 499 mg/100 ml).&#xD;
&#xD;
          -  Total cholesterol level more than 200 mg/100 ml&#xD;
&#xD;
          -  Male and female&#xD;
&#xD;
          -  Age 35 - 70 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Hypersensitivity of drugs&#xD;
&#xD;
          -  Liver toxicity&#xD;
&#xD;
          -  -Patients suffering from renal dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Misr University for science and technology</name>
      <address>
        <city>Giza</city>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 2, 2021</study_first_submitted>
  <study_first_submitted_qc>October 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Misr University for Science and Technology</investigator_affiliation>
    <investigator_full_name>Yasmine Farouk</investigator_full_name>
    <investigator_title>Teacher Assistant - clinical pharmacy department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>result and conclusion sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

